drugset
drugset / Trial / NCT07214935

A TQT Study of Effect of M2951 on Cardiac Repolarization

NCT07214935 ↗

Phase 1 Completed 36 enrolled Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
RandomizedCrossoverQuadruple-blindOther

Summary

The purpose of this study is to assess potential effects of M2951 on cardiac repolarization (i.e. prolongation of QT interval).

Timeline

Start
2022-11-08
Primary completion
2023-08-25
Completion
2023-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Evobrutinib Small molecule — Oral
Subject Moxifloxacin Small molecule — Oral

Indications

No indication recorded.